Pamrevlumab for IPF, Dapagliflozin in Critical Illness, Payer Involvement in Evidence Generation, and more
Editor’s Summary by Mary McGrae McDermott, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the August 6, 2024, issue.
